real-world incidence of ibrutinib-related cardiotoxicity in cll: insights from the lls registry
Published 7 months ago • 94 plays • Length 2:09Download video MP4
Download video MP3
Similar videos
-
1:09
assessing cardiovascular tolerability of zanubrutinib vs ibrutinib in pts with b-cell malignancies
-
4:29
first-line ibrutinib vs chemoimmunotherapy in cll: a real-world data analysis
-
6:05
real-world data on the effect of ibrutinib flexible dosing treatment strategies on ttnt in cll/sll
-
2:29
real-world comparison of ttnt with ibrutinib or acalabrutinib in cll
-
2:06
effects of dose adjustment of first-line ibrutinib on real-world dosing patterns and outcomes in cll
-
6:24
indiko biochemistry analyzer demonstration
-
4:53
human circulatory system
-
13:56
legends of cardiology: dr eugene m. braunwald
-
1:44
the impact of acalabrutinib treatment by line of therapy in patients with cll
-
1:38
front-line use of ibrutinib for cll in a real-world setting
-
10:42
a detailed overview of the current and emerging gene therapies for hemophilia a & b
-
5:52
understanding ultra high-risk cll and advances with ibrutinib therapy
-
1:45
the real-world outcomes of patients with cll who discontinue btki therapy
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
1:29
insights into the uses of ibrutinib for patients with waldenström’s macroglobulinemia
-
1:55
the alpine trial shows improved outcomes with zanubrutinib versus ibrutinib in r/r cll
-
3:00
five-year follow-up of the captivate trial: ibrutinib retreatment in patients with cll
-
2:14
real-world treatment patterns and comparative effectiveness of btki in patients with mcl
-
0:55
insights into the real-world evidence for c3 inhibition in the treatment of pnh
-
1:44
real-world outcomes of brexu-cel for r/r b-all: evidence from the cibmtr registry
-
6:09
brexu-cel in adults with r/r b-all: a real-world outcomes collaboration
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl